Table S1: Demographics of the post-COVID19 and healthy control cohort

Abbreviations: Gender, M (male), BAME (black, Asian and minority ethnic), COPD (chronic obstructive pulmonary disease), CPAP (continuous positive airway pressure), NIV (Non-invasive ventilation), IMV (invasive mechanical ventilation), CT (computed tomography), FEV1 (forced expiratory volume in 1 second), FVC (forced vital capacity), TLC (total lung capacity), TLCO (transfer factor of the lung for carbon monoxide), KCO (carbon monoxide transfer coefficient. Data presented as n (%n), median (IQR)

	Post-COVID19 (n = 38)	Healthy controls (n = 29)
ge (years)	56.5 (51.3-66.0)	49.0 (39.5 - 54.5)
ender, M (%n)	30 (78.9)	17 (58.6)
AME (%n)	22 (57.8)	N/A
omorbidities (%n)		
sthma	5 (13.2)	N/A
COPD Previous pneumothorax	1 (2.63)	N/A N/A
Hypertension	1 (2.63) 9 (23.7)	N/A N/A
schaemic heart disease	3 (7.89)	N/A
Type 2 diabetes mellitus	7 (18.4)	N/A
ype 2 diabetes memus	7 (10.4)	19/0
Smoking history		
Current smoker	1 (2.63)	2 (6.8)
Ex-smoker (>=10 pack year)	5 (13.2)	4 (13.7)
Non-smoker or ex-smoker <10 pack year)	32 (84.2)	17 (58.6)
Severity of acute illness		
Hospitalized (n/%)	36 (94.7)	N/A
Oxygen therapy only (moderate)	15 (39.5)	N/A
CPAP/ NIV (severe)	11 (28.9)	N/A
IMV (very severe)	10 (26.3)	N/A
Not hospitalized (moderate)	2 (5.26)	N/A
Length of hospital stay (days) [n=35]	10.0 (5.0-27.0)	N/A
Admission bloods [n=33]		
White cell count (x10°/L) [n=33]	6.80 (5.70-8.85)	N/A
Haemaglobin (g/L) [n=33]	143 (132-154)	N/A
Platelet (x10°/L) [n=33]	219 (195 – 271)	N/A
Neutrophil (x10°/L) [n=33]	5.90 (3.75-7.30)	N/A
Lymphocyte (x10º/L [n=33]	1.0 (0.70 – 1.45)	N/A
D dimer (microgram/L) [n=25]	965 (800-1622)	N/A
Fibrinogen (g/L) [n=31]	7.23 (6.21-8.09)	N/A
Ferritin (micrograms/L) [n=26]	762 (606-2329)	N/A
Sodium (mmol/L) [n=33]	134 (133-137)	N/A
Potassium (mmol/L) (n=31)	4.30 (4.1– 4.70)	N/A
Urea (mmol/L) [n=33]	5.30 (3.40-7.10)	N/A
Creatinine (micromol/L) [n=33]	86.0 (75.0-103)	N/A
Egfr (ml/min/1.73m2) [n=33]	79.0 (58.0-90.0)	N/A
Albumin (g/dL) [n=33]	33.0 (30.5-34.0)	N/A
C-reactive protein (mg/L) [n=33]	124 (84.1 – 223)	N/A
CT imaging (n=38) Days from admission to follow up CT [n=35]	117 (93.0-141)	N/A
Days from discharge to follow up CT [n=36]	97 (84.3-127)	N/A
Abnormal CT		N/A
Overall CT abnormality		N/A
Ground glass abnormality		N/A
Reticulation		N/A
Consolidation Bands		N/A
parius		N/A
Bronchoalveolar lavage fluid sampling (n=38) Days between admission and sampling [n=35]	153 (107 102)	N/A
Days between admission and sampling [n=35] Days between discharge and sampling [n=36]	153 (107-192) 135 (98.5-176)	N/A
	222 (2013 170)	
Lung function tests [n=36] Days between admission and lung function tests [n=33]	147 (106-185)	N/A
Days between discharge and lung function tests [n=34]	118 (92.0-171)	N/A
EV1 (L)	2.97 (2.36-3.60)	3.26 (2.8 - 3.6)
6 predicted FEV1	95.5 (86.5-103)	
VC (L)	3.73 (2.83 – 4.16)	3.96 (3.5 – 4.9)
6 predicted FVC	91.5 (83.5 – 96.8)	
rtc (t)	5.73 (5.09 – 6.33)	N/A
6 predicted TLC	89.0 (83.3 – 99.8)	N/A
rLCO ml/min/mmHg	6.39 (5.32 – 8.57)	N/A
% predicted TLCO	78.5 (67.3 – 96.8)	N/A
KCO ml/min/mmHg	1.37 (1.20-1.61)	N/A
% predicted KCO	99.0 (88.3-115)	N/A

BAL	% CD45						total cell nun	nbers				
highest value during hospitalisation	wcc i) dimer	Fibrinogen I	Ferritin	CRP	Lymphocytes	wcc	D dimer	Fibrinogen F	Ferritin	CRP	Lymphocytes
AM	-0.13	-0.08	0.08	-0.44	0.16	0.06	0.08	0.22	0.36	-0.19	0.0	2 0.2071
CD14+ Monocytes	0.04	-0.06	-0.25	0.62	-0.12	-0.12	0.07	0.10	-0.03	0.53	-0.2	-0.0333
CD14+, CD16+ Monocytes	0.05	0.16	-0.24	0.58	-0.29	-0.22	0.01	0.20	-0.17	0.50	-0.4	-0.1852
CD16+ Monocytes	-0.16	0.19	-0.33	0.25	-0.25	-0.02	-0.03	0.18	-0.17	0.30	-0.3	0.07909
total Monocytes	-0.14	0.09	-0.37	0.48	-0.26	-0.10	-0.10	0.05	-0.17	0.45	-0.4	0.05411
T cells	-0.04	0.17	0.01	0.25	-0.18	-0.02	0.06	0.29	0.14	0.25	-0.1	5 0.1051
NK T cells	0.34	0.02	0.14	0.38	0.01	-0.34	0.25	0.06	0.12	0.39	-0.1	9 -0.1739
B cells	0.07	0.49	0.30	0.27	0.30	0.06	0.06	0.50	0.35	0.26	0.3	0.1249
NK cells	-0.01	0.13	0.13	0.13	0.11	0.15	0.05	0.29	0.24	0.12	0.0	2 0.2258
Neutrophils	0.24	-0.29	-0.32	0.14	-0.23	-0.31	0.17	-0.28	-0.22	0.26	-0.3	-0.1499
Eosinophils	-0.07	-0.05	-0.12	0.40	-0.11	0.42	-0.18	0.00	-0.10	0.30	-0.2	7 0.4912
Lymphocytes	0.00	0.21	0.03	0.30	-0.12	-0.04	0.07	0.32	0.14	0.36	-0.1	3 0.08325

Table S2: Spearman Rank correlation between blood parameters during hospitalisation and immune cell populations in BAL at > 80 days post discharge

R values of Spearman Rank correlation between blood parameters and immune cell populations in BAL from pCOVID patients. WCC, D-dimer, fibrinogen, ferritin and CRP values are the highest recorded value during hospitalisation. N = 19; Values in green are R > 0.4, values in blue are R < -0.4.

Table S3. Demographics, blood tests, CT abnormalities, BALF findings and lung function tests at initial and follow bronchoscopy.

Abbreviations: Gender, M (male), BAME (black, Asian and minority ethnic), COPD (chronic obstructive pulmonary disease), CPAP (continuous positive airway pressure), NIV (Non-invasive ventilation), IMV (invasive mechanical ventilation), CT (computed tomography), FEV1 (forced expiratory volume in 1 second), FVC (forced vital capacity), TLC (total lung capacity), TLCO (transfer factor of the lung for carbon monoxide), KCO (carbon monoxide transfer coefficient Data presented as n (%n), median (IQR)

•	, ,
	pCOVID (n = 3)
Age (years)	62 (50-71)
Gender, M (%n)	3 (100)
BAME (%n)	2 (66.7)
Comorbidities (%n)	0 (0)
Asthma COPD	0 (0) 0 (0)
Previous pneumothorax	0 (0)
Hypertension	3 (0)
Ischaemic heart disease	0 (0)
Type 2 diabetes mellitus	0 (0)
Smoking history	
Current smoker	0 (0)
Ex-smoker (>=10 pack year)	1 (33.3)
Non-smoker or ex-smoker <10 pack year)	2 (66.7)
Severity of acute illness	
Hospitalized (n/%)	3 (100)
- Oxygen therapy only (moderate)	0 (0)
- CPAP/ NIV (severe)	0 (0)
- IMV (very severe)	3 (100)
Not hospitalized (moderate)	0 (0)
Length of hospital stay (days) [n=35]	18 (11-28)
Admission bloods [n=3]	
White cell count (x10°/L)	9.3 (7.4 – 10.3)
Haemaglobin (g/L)	140 (130 – 151)
Platelet (x10°/L)	243 (219 – 524)
Neutrophil (x10°/L)	7.7 (6.1 – 9.1)
Lymphocyte (x10°/L	0.9 (0.7 – 0.9)
D dimer (microgram/L)	1920 (965 – 2874)
Fibrinogen (g/L)	7.5 (7.2 – 8.6)
Ferritin (micrograms/L)	745 (738 – 6032)
Sodium (mmol/L) Potassium (mmol/L)	132 (132 – 137) 4.2 (4.2 – 4.9)
Urea (mmol/L)	5 (4.4 – 8.1)
Creatinine (micromol/L)	95 (95 – 135)
Egfr (ml/min/1.73m²)	70 (49 – 81)
Albumin (g/dL)	33 (31 – 34)
C-reactive protein (mg/L)	229 (218 – 255)
Treatment during follow up period	. (00.0)
Steroids Antibiotics	1 (33.3) 1 (33.3)
Antibiotics	1 (33.3)
1 year follow up CT imaging (n=3)	
Days from admission to follow up CT	388 (382 – 389)
Days from discharge to follow up CT	371 (354-377)
1 year bronchoalveolar lavage fluid sampling (n=3)	
Days between admission and sampling	410 (402 – 412)
Days between discharge and sampling	392 (374 – 401)
1 year Lung function tests [n=3]	
Days between admission and lung function tests	394 (389 – 409)
Days between discharge and lung function tests [378 (366-391)
FEV1 (L)	3.3 (2.9-3.9)
% predicted FEV1	104 (97-123)
70 predicted I LV 1	
FVC (L)	3.9 (3.5 – 4.4)
FVC (L) % predicted FVC	101 (91 – 106)
FVC (L)	




Figure S1: Flow gating strategy and immune cell proportions in post-COVID19 BAL

(A) Proportional representation of immune cell populations in BAL from healthy controls and post-COVID19 patients. AM = airway macrophages. (B) Proportions of immune populations (% of live, leukocytes) in peripheral blood from healthy controls and post-COVID19 patients. CD14+ classical monocytes, CD3+ T cells, CD19+ B cells, CD56+ NK cells, CD3+/CD56+ NKT cells. Post-COVID19 patients were split by severity of acute disease.

Data are presented as mean \pm SEM. Healthy controls n = 16, post-COVID-19 patients n = 22, moderate n = 6, severe n = 9, very severe n = 7. Statistical significance was tested by Mann Whitney U test, Kruskal Wallis test + Dunn's multiple comparison test or Spearman Rank test. *P < **P < 0.01.




Figure S2. Post-COVID19 effects on the airway proteome are not mirrored in the blood (A-B) Hierarchical clustering of samples and proteins using all 435 proteins measured in A) BAL and B) plasma. Z score normalized protein levels are shown. **(C)** Median NPX values for the 22 proteins that were significantly differentially abundant (5% FDR) in BAL from post-COVID-19 patients versus healthy controls. **(D)** Comparison of effect size estimates in BAL versus plasma for the 22 proteins. Each point represents a protein. The x-axis shows the estimated log₂ fold change in BAL while the y-axis shows the estimated log₂ fold change in plasma.




Figure S3. Statistical evidence for proteomic differences between post-COVID19 and healthy controls

(A) QQ plots showing the expected distribution of –log10 P-values under the null hypothesis of no association between each protein and case/control status compared to the actual –log10 P-values observed in the analysis. The plots shows departure from the diagonal, more marked in BAL. **(B)** Histogram of observed nominal p-values from linear regression of each protein on case/control status. The p-values are not uniformly distributed between 0 and 1. Again this is more marked in BAL.




Figure S4. WGCNA identification of the blue module protein network in the post-COVID19 airway

(A) heatmap displaying Z-score normalised protein abundance for the proteins that form the "blue" eigenprotein module in post-COVID19 and healthy controls in BAL. (B) Network representation of proteins in the 'blue' module and their interconnections. An edge in the network represents a relationship between proteins defined using String-db. Predicted hub proteins within the network are stated.






Figure S5. Activation marker expression on CD8 TRM in the post-COVID19 airway against patient severity

Airway CD103- (top) and CD103+ (bottom) CD69+ CD8 T cells were identified in post-COVID19 BAL by spectral deconvolution flow cytometry. Expression of CD27, CD127, HLA-DR, CD28, CD38 and PD-1 was then analysed against acute severity. Geometric mean fluorescence intensity (gMFI) is shown. Each dot represents an individual donor.



Methods Figure 1. 11-colour immune phenotyping flow cytometry panel

Gating strategy to determine immune cell populations in BAL from healthy controls and pCOVID patients. After selecting for live, CD45⁺ cells, the following populations were analysed: CD206⁺ airway macrophages, CD14⁺ classical monocytes, CD16⁺ non classical monocytes, CD3⁺/CD56⁺ NK T cells, CD19⁺ B cells, CD56⁺ NK cells, Siglec 8⁺ Eosinophils and CD177⁺ neutrophils.



Methods Figure 2. Spectral deconvolution high parameter gating strategy

Gating strategy for 34-marker spectral deconvolution flow cytometry panel. Post-COVID19 BAL cells are shown.